Fatigue in patients with prostate cancer receiving hormone therapy
Fatigue in patients with prostate cancer receiving hormone therapy
复制标题
DOI：
10.1016/s0959-8049(00)00084-8
复制
发表时间：
2000-06-01
影响因子：
8.4
通讯作者：
Richards, M
中科院分区：
文献类型：
--
作者：
Stone, P;Hardy, J;Richards, M
这项研究的目的是确定前列腺癌患者在接受一线激素治疗(环丙孕酮和葛根素)治疗前和治疗3个月后的方便样本中疲劳感的患病率、严重程度和相关性。患者(n=62)的严重疲劳被定义为疲劳严重程度量表(FSS)上的分数大于一组没有癌症的老年志愿者的第95个百分位数。受试者还完成了关于疲劳、生活质量、焦虑/抑郁和个性的其他问卷。受试者接受了营养评估、自愿肌肉功能和注意力测试。基线时“严重疲劳”的患病率为8/58(14%)。治疗3个月后FSS评分中位数较治疗前显著增加。在多变量分析中，心理困扰可以解释疲劳分数变化的28%。治疗与自主肌肉功能的降低、肌肉体积的丧失、男子气概和能力的下降、疼痛的改善以及恶心/呕吐的减少有关。疲劳是激素治疗的一个重要但未被充分认识的副作用。(C)2000爱思唯尔科学有限公司。保留所有权利。
The aim of this study was to determine the prevalence, severity and correlates of fatigue in a convenience sample of outpatients with prostate cancer prior to and following 3-months treatment with first-line hormone therapy (cyproterone acetate and goserelin). 'Severe fatigue' in the patients (n = 62) was defined as a score on the Fatigue Severity Scale (FSS) greater than the 95th percentile of a group of elderly volunteers without cancer. Subjects also completed other questionnaires about fatigue and about quality of life, anxiety/depression and personality. Subjects underwent a nutritional assessment, tests of voluntary muscle function and attention. The prevalence of 'severe fatigue' at baseline was 8/58 (14%). Median FSS scores increased significantly after 3 months treatment. On multivariate analysis psychological distress explained 28% of the variance in fatigue scores. Treatment was associated with a reduction in voluntary muscle function, loss of muscle bulk, a decline in virility and potency, an improvement in pain and a reduction in nausea/vomiting. Fatigue is an important but under-recognised side-effect of hormone therapy. (C) 2000 Elsevier Science Ltd. All rights reserved.